Transforming Outcomes for Multiple Myeloma & Amyloidosis Patients | Prof. Eli Muchtar

追加: 2026-06-03

[00:00:00]After 10 years at the Mayo Clinic, I came to Sheba to build something unique in this region. [music] Multiple myeloma, systemic amyloidosis, and plasma cell disorders program, bringing together diagnostics, innovation, and care under one roof.

[00:00:17]At its core, our technologies found in only a handful of centers worldwide.

[00:00:22]Mass spectrometry-based [music] amyloid typing and advanced monoclonal protein detection. Together, they enable precise disease characterization [music] at the molecular level. Our academic CAR-T cell program gives patients earlier access to cutting-edge cellular therapies, particularly in high-risk myeloma and AL amyloidosis, where deep responses are needed.

[00:00:44]Faster diagnosis and early access to innovative therapies, both are essential to transforming outcomes and quality of life for our patients. At Sheba, this is what we work towards >> [music] >> for every patient.